Veterinary Respiratory Disease Treatment Market

Veterinary Respiratory Disease Treatment Market: Global Industry Analysis and Opportunity Assessment 2016-2026

  • Ongoing
  • August 2020
  • REP-GB-2526
Veterinary Respiratory Disease Treatment Market

  • US$5,000
  • US$7,500
  • US$10,000

This Veterinary Respiratory Disease Treatment market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Veterinary Respiratory Disease Treatment market.

Veterinary respiratory diseases are the most common disease that affects livestock and small animals. Veterinary respiratory diseases are the second leading cause of mortality in various animals. Veterinary respiratory disease caused to the animals varies from animal to animal, and it depends on upon the causative agent. Veterinary respiratory disease resulting from different types of bacteria (bacteria, viruses, weak immune system, temperature fluctuations and improper ventilation are the few factors responsible for causing veterinary respiratory diseases. Due to veterinary respiratory diseases, it is leading to high mortality rates of animals and causing economic losses. For instance, the bovine respiratory disease is most common in cattle and swine respiratory disease in pigs. Bovine respiratory disease mostly caused by the bacterial agents Pasteurella multocida, Histophilus somni, Mycoplasma bovis, and Mannheimia haemolytica. Various medicines are available in the market to treat Veterinary respiratory diseases. Most commonly used drugs to treat veterinary respiratory diseases are antimicrobial agents, Non-steroidal anti-inflammatory drugs (NSAID’s), Bronchodilators, Mucolytic agents, Oral rehydration fluids, and immunomodulators. However, treatments are becoming ineffective owing to increase in bacterial, viral resistance in the animals and lack of proper diagnosis are significant factors resulting increase in veterinary respiratory diseases. Hence newer drugs are coming into the market to treat veterinary respiratory disease conditions. In 2011, Merial (Boehringer Ingelheim), launched Zactran (Gamithromycin) to treat and control bovine respiratory disease conditions. In 2008, Zoetis (Pfizer), got EU approval for Draxxin® (tulathromycin) to treat Haemophilus parasuis (Glässer’s disease) in pigs, the uniqueness of the drug is it acts for ten days this intends to reduce the frequent dosage to the animals. In 2015, Ceva group launched respiratory vaccine to prevent from Mycoplasma hyopneumoniae infections. To decrease the antibacterial resistant animals researchers are exploring new therapeutic approaches like bacteriophage therapy and bacterial peptides to treat veterinary respiratory disease conditions.

Veterinary Respiratory Disease Market: Drivers and Restraints

Market Growth Analysis

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

COVID -19 : Impact Analysis

Request the coronavirus impact analysis across industries and markets

Request Covid -19 Impact

The global market for veterinary respiratory disease market is driven due to increase in respiratory infections, lack of drugs to treat specific pathogens, to decrease the mortality rates of animals are driving the growth of veterinary respiratory disease market during the forecast period. In 2011, U.S Department of Agriculture’s National Animal Health Monitoring System (NAHMS) had conducted study to understand the treatment cost and incidence of respiratory diseases in cattle. The results showed that around 16.2 percent of cattle affected with respiratory diseases and treatment cost for cattle is the $23.60/per case. The cost for treating veterinary respiratory disease has increased significantly over the years. In the UK, cattle industry spends around 60 million euros annually to treat respiratory disease conditions. Veterinary respiratory disease is more commonly affected by the young calves and animals this due to improper development of immune system. The major restraints of the market are the cost of the drugs, government regulations to reduce the usage of antibiotics are hindering the growth of this market.

Veterinary Respiratory Disease Market: Segmentation

Veterinary respiratory disease market is segmented on the basis of drug classification, distribution channel, and end user.

Veterinary Respiratory Disease Market: Overview

Veterinary Respiratory Disease Market: Regional Overview

Veterinary Respiratory Disease Market: Players

Some of the players in global veterinary respiratory disease market include Zoetis, Merck & Co., Inc., Eli Lilly Company, Virbac group, Bayer, Vetoquinol, Boehringer Ingelheim, Ceva and Bimeda animal health.

The report is a compilation of first-hand information, qualitative, and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Unique Requirements? Customize this Report

  • Customize by Region, Country, Application, Product, & other segments
  • Integrate our Insights with your Existing Data
  • Determine the scope of the study to suit your requirements

Let FMI Help You!

  • Gain Insights on Key Veterinary Respiratory Disease Treatment Market Impacting Forces
  • Know the Winning Strategies of Market Leaders
  • Get Deep-Dive Analysis on Each Segment
  • Identify the Sources that will Drive Top-Line Revenue

Based on the drug classification, the veterinary respiratory disease market is segmented into the following:

  • Antibiotics
    • Penicillins
    • Aminoglycosides
    • Cephalosporins
    • Others
  • Antiparasitics
  • NSAID’s
  • Antiviral
  • Vaccines

Based on the route of administration, the veterinary respiratory disease market is segmented into the following:

  • Oral
  • Parenteral
  • Other

Based on the distribution channel, the veterinary respiratory disease market is segmented into the following:

  • Veterinary Pharmacies
  • Retail Pharmacies
  • E-commerce

Cost effective, long-acting drugs would create attractive growth opportunities for the veterinary respiratory disease market over the forecast period. To treat respiratory diseases in cattle critically important, antibiotics like aminoglycosides, cephalosporins and penicillins are most commonly used followed by macrolides and fluoroquinolones. In the case of respiratory diseases in pigs, 47% of tetracyclines are used followed by pencillins (21%), macrolides (10%) and potentiated sulphonamides (8%). Rifampicin is commonly used to treat respiratory infections in horses. In the veterinary respiratory disease market antibiotics and vaccines occupies the significant share in the market and dominates during the forecast period. Based on distribution channel, veterinary pharmacies dominated the current market and expected to dominate during the forecast period. The number of e-commerce pharmacies is increasing due to increasing penetration of internet across the globe. Both parenteral and oral routes are most commonly used to treat the veterinary respiratory diseases.

Veterinary Respiratory Disease Market: Regional Overview

Region-wise, the global veterinary respiratory disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America dominated the global market for veterinary respiratory disease owing to established health care and practiced veterinary practitioners are driving the growth of this market. Asia-Pacific is expected to surpass the European market during the forecast owing to increase in the cattle population.

Veterinary Respiratory Disease Market: Players

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Western Europe (Germany, Italy, U.K, Spain, France, Nordiccountries, BENELUX)
  • Eastern Europe (Russia, Poland, Rest of Eastern Europe)
  • Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle Eastand Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint.
Frequently Asked Questions

Why choose FMI?
  • With a global presence and a trusted partner to several Fortune 500 firms, FMI covers 1 billion+ data points to build a diversified portfolio for market benchmarking
  • Market Reports researched and peer reviewed by industry experts from across the globe
  • We follow a multi-dimensional method of analysis monitoring a three-layer data validation process
  • In addition to demand-side market assessment, our data triangulation methodology involves supply-side research
  • Primary research includes mandatory field interviews with stakeholders involved
  • Customizing reports according to client specification is also our forte
  • The current and future market size, covering each aspect and nuanced trends across key national and geographic markets
  • An overview of the market report, providing an imperative visual of the varied market subdivisions and overall forecast statistics in terms of value and volume
  • Extensive database and key dynamics elevating the market with varied verticals associated
  • Underlying Veterinary Respiratory Disease Treatment Market forces that are compelling consumers or businesses to purchase the product
  • How novel technologies and consumer-centric innovations will create new value-adding opportunities for companies active in the Veterinary Respiratory Disease Treatment Market
  • What will be environment and regulatory impacts on the market over the next decade
  • Investment Feasibility Matrix - It shows returns on investment, level of competition, success rate of investment, and potential risks associated with the market. The analysis shows that the competition is high in the established market, while the returns for short-term investment are also taken into consideration
  • Relative Maturity Mapping – The relative maturity is measured according to three growth phases (growth, maturity, decline)
  • Relative PLC (Product Life Cycle) – Analysis of the emergence of prominent players and competitive test prices which are driving factors behind every market. (expected market behavior, observed market behavior, expected market performance, observed market performance)
Get in touch
Harish Tiwari

Harish Tiwari

Global Head - Business Development

Akshay Godge

Akshay Godge

Client Partner - Global Business Development

Our Clients

Request Sample Request customization Request Methodology